Last updated: February 15, 2026
Product Overview:
NDC 00781-2384 is the branded formulation of Jemperli (dostarlimab-gxly), developed by GlaxoSmithKline. It is an immune checkpoint inhibitor used for treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, including endometrial cancer.
Market Landscape:
The drug entered the oncology market in 2021 after FDA approval. The global immuno-oncology market is projected to grow at a compound annual growth rate (CAGR) of approximately 11.2% from 2022 to 2028, driven by expanding indications and increasing adoption of immunotherapies.[1]
Key Competitors:
- Merck’s Keytruda (pembrolizumab)
- Bristol-Myers Squibb's Opdivo (nivolumab)
- AstraZeneca's Imfinzi (durvalumab)
Market Penetration Factors:
- Indication overlap with established PD-1 inhibitors
- Approval expansion to additional cancer types
- Physician familiarity with immune checkpoint inhibitors
- Cost and reimbursement considerations
Pricing Dynamics:
Jemperli's initial wholesale acquisition cost (WAC) in the U.S. approximates $11,200 per 50 mg dose, aligning with other PD-1 inhibitors. Commercial pricing for oncology immunotherapies tends to be around $10,000–$13,000 per treatment cycle, depending on dosage and indication.
Price Projections (2023-2028):
- Short-term (2023-2024): Stable pricing around $11,000–$12,000 per dose as market adoption grows.
- Mid-term (2025-2026): Potential price erosion of 5-10% due to increased competition and biosimilar entry.
- Long-term (2027-2028): Price stabilization forecast at $9,500–$10,500 per dose with broader indication expansion and improved payer coverage.
Market Adoption Assumptions:
- Annual sales volume expected to reach 50,000 doses globally by 2028, up from approximately 10,000 doses in 2022.
- Peak revenue projection around $600 million in 2028, underpinned by expanded indications and increased uptake.[2]
Regulatory and Reimbursement Impact:
- Expanded approvals in Europe and Asia will increase market addressability.
- Reimbursement decisions will influence net price; favorable policies could sustain higher price points.
- Cost-effectiveness analyses are critical in payer decisions, influencing formulary placement.
Implications for Stakeholders:
- Investors should monitor competition, biosimilar timelines, and new indications.
- Healthcare providers will weigh efficacy and cost in treatment choice.
- Manufacturers must strategically price and position Jemperli within the rapidly evolving immunotherapy landscape.
Key Takeaways
- NDC 00781-2384 (Jemperli) entered a highly competitive immunotherapy market with key rivals being Merck’s Keytruda and BMS's Opdivo.
- Initial pricing aligns with peers at approximately $11,000 per dose, with expected gradual price erosion over five years.
- Market expansion and indication breadth will likely drive sales volume, possibly reaching $600 million annually by 2028.
- Competitive pressures, biosimilar entry, and reimbursement policies are factors influencing long-term price stability.
- Strategic positioning and regulatory approvals are essential for maximizing market share and revenue.
FAQs
Q1: What are the primary drivers of Jemperli’s market growth?
Indication expansion, clinical evidence supporting efficacy, physician familiarity with immune checkpoints, and reimbursement coverage.
Q2: How does Jemperli compare pricing-wise to its competitors?
Pricing per dose is similar to pembrolizumab and nivolumab, approximately $11,000–$12,000, with potential for slight differences based on dosing and indication.
Q3: What factors could lead to price reductions for Jemperli?
Entry of biosimilars, increased competition, payer negotiations, and broader use of cost-effective therapies.
Q4: How does indication expansion impact future sales?
Broader approval to additional cancer types boosts patient population and drives sales volume growth.
Q5: What regulatory considerations could influence market access?
Approval in key markets like Europe, China, and Japan increases access; reimbursement policies determine pricing flexibility.
References
[1] MarketsandMarkets. "Immuno-Oncology Market by Therapy, Application, and Region." 2022.
[2] EvaluatePharma. "Worldwide Immuno-Oncology Market Forecast," 2022.
[3] FDA, "Jemperli (dostarlimab-gxly) Approval Notification," 2021.
